Skip to content
ES
MARKETS / NASDAQ / CPIX
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Cumberland Pharmaceuticals Inc. CPIX

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$44.5M
▲ 17.6% YoY
$-2.8M
$4.8M
In brief

What this company does

Our primary target markets are hospital acute care, gastroenterology and oncology. We promote our approved products through our hospital, field and oncology sales divisions in the United States. We were incorporated as a Tennessee corporation in 1999 and have been headquartered in Nashville, Tennessee since inception. During 2009, we completed an initial public offering of our common shares and listing on the Nasdaq stock exchange. As of December 31, 2025, we had 93 employees.

Written from the business description in Cumberland Pharmaceuticals Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 9 March 2026. Every sentence was checked against that document before publication.

Growth
USD 44.5M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 44.5 · Net income -2.8
20M40M-4M200920112013201520172019202120232025
Compound annual growth
+2.0%
+4.4%
+47.7%
−0.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +4.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−6 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -6.3% · Net -6.4%
500%1000%-200%-400%200920112013201520172019202120232025
ROE
FY2025 · ROE -11.9%
2%4%6%-10%-20%200920112013201520172019202120232025
Gross margin85.0%
Operating margin-6.3%
Net margin-6.4%
Return on assets-3.8%
EBITDAUSD 1.4M

Each USD of equity lost 12 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 4.8
4M8M200920112013201520172019202120232025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks -4.5
10M20M-2M-4M200920112013201520172019202120232025
Dividends paid—
Net buybacksUSD -4.5M
Share of profit-0.0%
Consecutive raises—

Total assetsUSD 76.8M
EquityUSD 24.9M
CashUSD 11.4M
Gross debtUSD 0.00
Net debtUSD -11.4M
Current ratio1.01×

The company holds more cash than debt.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.10.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.0−0.00.00.00.00.0
EBITDA $B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.00.0−0.00.00.00.00.0
Income tax $B0.0−0.00.00.00.00.0−0.00.00.0−0.00.00.0−0.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.0−0.00.00.00.00.0
Free cash flow $B0.0−0.00.00.00.00.00.00.0−0.00.00.00.00.00.00.0−0.0−0.0
EPS, diluted $−0.19−0.46−0.44−0.38−0.24−0.22−0.23−0.45−0.50−0.060.040.14−0.110.300.280.120.17
Dividend / sh $·················
Payout %·················
ROE %−11.9−24.7−19.1−14.1−7.8−6.8−6.6−11.6−11.6−1.30.93.0−2.56.97.03.2·
Shares out B0.010.010.010.010.010.010.020.020.020.020.020.020.020.020.020.02·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inTennessee
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image